Q2 2020 Revenue Increase of 23% Over Prior Year Period REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended June 30, 2020. Recent Highlights Revenue of $66.3 million for the second quarter of 2020, an increase of 23% over the corresponding...